文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

不同液体复苏类型对早期脓毒症与脓毒性休克患者糖萼的影响及临床意义:单中心前瞻性随机对照试验

[Impact and clinical significance of different types of fluid resuscitation on the glycocalyx in patients with early sepsis and septic shock: a single center, prospective, randomized controlled trial].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2025-01-01
一句话结论平衡晶体液联合白蛋白较单用平衡晶体液未降低糖萼标志物多配体蛋白聚糖-1,但8小时和24小时乳酸更低、乳酸清除率更高,28天和90天预后无差异。

单中心前瞻性随机对照试验纳入河北医科大学第四医院重症医学科2023年4月至10月收治的66例早期脓毒症与脓毒性休克需液体复苏患者,随机分为平衡晶体液+白蛋白组(44例)与平衡晶体液组(22例)。两组复苏前后血浆多配体蛋白聚糖-1浓度无统计学显著差异,均呈先升后降趋势;对照组复苏后8小时和24小时多配体蛋白聚糖-1显著高于复苏前基线,试验组各时间点无统计学显著差异。试验组8小时和24小时乳酸绝对值更低、乳酸清除率更高,但28天和90天死亡率、住院时间、ICU住院时间、机械通气时间、血液净化时间、器官损伤数目及并发症无统计学显著差异。多因素Logistic回归显示BMI与90天死亡率独立相关。作者认为联合白蛋白可改善乳酸清除,但需大规模随机对照试验进一步验证。

要点

  • 平衡晶体液+白蛋白组与平衡晶体液组复苏前后血浆多配体蛋白聚糖-1浓度无统计学显著差异,均呈先升后降趋势。
  • 对照组复苏后8小时和24小时多配体蛋白聚糖-1显著高于复苏前基线[ng/L:19.02(14.41, 27.80)、18.95(12.40, 22.50)vs. 14.67(11.57, 21.14),均P<0.05],试验组各时间点无统计学显著差异。
  • 试验组8小时和24小时乳酸绝对值更低[mmol/L:8小时1.30(1.00, 1.88)vs. 1.60(1.30, 3.05),24小时1.15(0.80, 1.78)vs. 1.55(1.08, 2.05),均P<0.05]。
  • 试验组8小时和24小时乳酸清除率更高[8小时45%(27%, 56%)vs. 20%(-4%, 46%),24小时55%(34%, 70%)vs. 34%(-14%, 59%),均P<0.05]。
  • 两组28天和90天死亡率、住院时间、ICU住院时间、机械通气时间、血液净化时间、器官损伤数目及并发症无统计学显著差异;BMI与90天死亡率独立相关(OR=1.991,95%CI 1.023-3.387,P=0.043)。

适用人群与场景

  • 河北医科大学第四医院重症医学科2023年4月至10月收治的早期脓毒症与脓毒性休克患者,经容量状态评估后需液体复苏者。

处置流程与药物剂量

  • 试验组予平衡晶体液+白蛋白复苏,对照组予平衡晶体液复苏;两组复苏过程中液体复苏量、血管活性药物使用及氧合指数无统计学显著差异。

研究设计与关键结果

  • 单中心前瞻性随机对照试验,共纳入66例,试验组44例、对照组22例,两组基线资料均衡可比;试验组基线白蛋白显著低于对照组(g/L:28.7±4.5 vs. 31.6±4.2,P<0.05)。
  • 两组复苏前后血浆多配体蛋白聚糖-1浓度无统计学显著差异,均呈先升后降趋势;对照组复苏后8小时和24小时多配体蛋白聚糖-1显著高于复苏前基线[ng/L:19.02(14.41, 27.80)、18.95(12.40, 22.50)vs. 14.67(11.57, 21.14),均P<0.05],试验组各时间点无统计学显著差异。
  • 全部患者血浆多配体蛋白聚糖-1与SOFA评分在复苏前呈正相关(r=0.247,P=0.046),与白蛋白水平在复苏后24小时呈负相关(r=-0.308,P=0.012)。
  • 试验组8小时和24小时乳酸绝对值更低[mmol/L:8小时1.30(1.00, 1.88)vs. 1.60(1.30, 3.05),24小时1.15(0.80, 1.78)vs. 1.55(1.08, 2.05),均P<0.05],乳酸清除率更高[8小时45%(27%, 56%)vs. 20%(-4%, 46%),24小时55%(34%, 70%)vs. 34%(-14%, 59%),均P<0.05]。
  • 两组28天和90天死亡率、住院时间、ICU住院时间、机械通气时间、血液净化时间、器官损伤数目及并发症无统计学显著差异;液体复苏量、血管活性药物使用及氧合指数无统计学显著差异。
  • 多因素Logistic回归显示BMI与90天死亡率独立相关(OR=1.991,95%CI 1.023-3.387,P=0.043)。

证据类型、等级与局限

  • 证据类型:单中心前瞻性随机对照试验。
  • 局限:原文报告需大规模随机对照试验进一步验证。

对床旁实践的改变

  • 作者认为,与平衡晶体液相比,平衡晶体液联合白蛋白用于脓毒症患者液体复苏具有更低的乳酸水平和更好的乳酸清除效果,但尚需大规模随机对照试验进一步验证。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the risks and benefits of different resuscitation fluids in patients with early sepsis and septic shock by observing and comparing clinical indicators, clinical outcomes, and the concentration changes of glycocalyx biomarkers, and to determine how to appropriately select suitable resuscitation fluids for sepsis patients to aid fluid therapy.

METHODS: A single center, prospective, randomized controlled trial was conducted. Patients with early sepsis and septic shock who have required fluid resuscitation after capacity status assessment admitted to the department of critical care medicine of Fourth Hospital of Hebei Medical University from April to October 2023 were enrolled. Patients were randomly assigned to either the experimental group (balanced crystalloid solution+albumin) or the control group (balanced crystalloid solution) by a random number table method. Clinical data of both groups of patients before and after resuscitation at 3, 8, and 24 hours were monitored, and blood samples were collected, enzyme-linked immunosorbent assay (ELISA) was used to measure the concentration of plasma glycocalyx biomarker syndecan-1. The 28-day and 90-day survival rates and complications were also assessed.

RESULTS: A total of 66 patients were enrolled, including 44 in the experimental group and 22 in the control group. The baseline data of two groups were balanced and comparable. There was no statistically significant difference in the plasma concentration of syndecan-1 between the experimental group and the control group before and after resuscitation, and both showed a trend of first increasing and then decreasing. However, the plasma syndecan-1 level in the control group at 8 hours and 24 hours after resuscitation were significantly higher than the baseline level before resuscitation [ng/L: 19.02 (14.41, 27.80), 18.95 (12.40, 22.50) vs. 14.67 (11.57, 21.14), both P < 0.05], while there was no statistically significant difference at any time point within the experimental group. The correlation analysis between plasma syndecan-1 level and lactic acid, albumin, and sequential organ failure assessment (SOFA) in all patients showed that a positive correlation between syndecan-1 level and SOFA score before resuscitation (r = 0.247, P = 0.046), and a negative correlation between syndecan-1 level and albumin level at 24 hours after resuscitation (r = -0.308, P = 0.012). There were no statistically significant differences in 28-day and 90-day mortality, length of hospital stay, length of intensive care unit (ICU) stay, duration of mechanical ventilation, blood purification time, number of organ injuries, and complications between the two groups. However, the baseline albumin level in the experimental group was significantly lower than that in the control group (g/L: 28.7±4.5 vs. 31.6±4.2, P < 0.05). Analysis of clinical treatment data showed that compared with the control group, the experimental group had lower absolute lactate level at 8 hours and 24 hours after resuscitation [mmol/L: 8 hours was 1.30 (1.00, 1.88) vs. 1.60 (1.30, 3.05), 24 hours was 1.15 (0.80, 1.78) vs. 1.55 (1.08, 2.05), both P < 0.05], and higher lactate clearance rate [8 hours was 45% (27%, 56%) vs. 20% (-4%, 46%), 24 hours was 55% (34%, 70%) vs. 34% (-14%, 59%), both P < 0.05]. However, there were no statistically significant differences in the amount of fluid resuscitation, use of vasoactive drugs, and oxygenation index between the two groups during the resuscitation process. Multivariate Logistic regression analysis showed that body mass index (BMI) was independently correlated with 90-day mortality [odds ratio (OR) = 1.991, 95% confidence interval (95%CI) was 1.023-3.387, P = 0.043].

CONCLUSIONS: There are no significant difference in plasma syndecan-1 level during fluid resuscitation of early sepsis and septic shock patients using balanced crystalloid fluid and balanced crystalloid fluid combined with albumin resuscitation, and there are no statistically significant differences in the impact on 28-day and 90-day prognosis, length of hospital stay, complications, and other aspects of the patients. However, compared to balanced crystalloid fluid, the combination of balanced crystalloid fluid and albumin for fluid resuscitation in sepsis patients has lower lactate level and better lactate clearance effect, but further validation is still needed through large-scale randomized controlled trials.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Dong L, Wu X, Zhao C, et al. [Impact and clinical significance of different types of fluid resuscitation on the glycocalyx in patients with early sepsis and septic shock: a single center, prospective, randomized controlled trial]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2025. PMID: 40201993. doi:10.3760/cma.j.cn121430-20240711-00583

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。